Document is current
Any future updates will be listed below
-
Authors
Scott, Xavier O.
Kerr, Nadine A.
Sanchez-Molano, Juliana
de Rivero Vaccari, Juan Pablo
Hadad, Roey
De La Cruz, Alicia
Larsson, H. Peter
Dietrich, W. Dalton
Keane, Robert W.
-
Funding
Funding for this research was provided by:
American Heart Association (AWD-006857)
National Institutes of Health (R01NS113969)
National Institutes of Health (RF1NS125578)
National Institutes of Health (RF1NS125578)
National Institutes of Health (R01NS113969)
National Institutes of Health (R01NS113969)
National Institutes of Health (R01HL131461)
National Institutes of Health (R01HL131461)
National Institutes of Health (RF1NS125578)
National Institutes of Health (R01NS113969)
- License Information
-
More Information
Article History
Received: 31 July 2024
Revised: 23 October 2024
Accepted: 11 November 2024
First Online: 18 November 2024
Declarations
:
: JPdRV, RWK and WDD are co-founders and managing members of InflamaCORE, LLC and have licensed patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. JPdRV, RWK and WDD are Scientific Advisory Board Members of ZyVersa Therapeutics.
: The manuscript has been reviewed and approved by all the authors. All authors have read the journal’s authorship agreement and policy on disclosure of potential conflicts of interest.
